Revenue $15.03B, up 2.6% on a year earlier. Oncology revenue $4.17B, down 5.1%. U.S. revenues $15.03B, up 69.0%. Diluted EPS -$0.04 against $0.51.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $14.65B | +2.6% |
| Operating income | -$653.00M | $3.17B | $3.04B | -121.5% |
| Net income | -$248.00M | $2.69B | $2.91B | -108.5% |
| Diluted EPS | -$0.04 | $0.47 | $0.51 | |
| Operating cash flow | $835.00M | $2.62B | -$582.00M | |
| Capital expenditures | -$533.00M | -$436.00M | -$618.00M | |
| Free cash flow | $302.00M | $2.18B | -$1.20B | |
| Dividend per share | $0.43 | $0.43 | $0.43 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Oncology revenue | $4.17B | $4.39B | -5.1% |
| U.S. revenues | $15.03B | $8.89B | +69.0% |
| Specialty Care revenue | $3.35B | $4.38B | -23.4% |
| Vyndaqel family revenue | $1.76B | $1.61B | +9.1% |
| Primary Care revenue | $5.50B | $5.54B | -0.7% |
| Prevnar family revenue | $1.34B | $1.38B | -3.3% |
| Eliquis Revenue | $2.42B | $2.00B | +21.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Pfizer (PFE) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/PFE/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
